In order to increase the prognostic significance of polymerase chain reaction (PCR) data it has been suggested that quantitative PCR can be used to measure tumor burden. However, this option has not yet been definitely supported or refuted in patients with follicular lymphoma (FL). We decided to evaluate whether knowledge of the quantitative level of minimal residual disease and its variations can be of use in the management of FL patients.
Methods
We used qualitative and competitive PCR to study 11 patients with refractory or relapsed FL harboring the t(14;18) translocation who underwent autologous (nine patients) or allogeneic (two patients) stem cell transplantation (SCT). Competitive PCR was performed with a multiple competitor carrying specific sequences including Bcl2/lgH MBR and mcr, and the β-globin gene.
Results
After a median post-SCT follow-up of 44 months (range, 12-62), overall survival was 91% and disease-free survival 82%. The quantitative PCR data showed that: 1) effective chemotherapy before SCT substantially (1-2 log) reduced the tumor burden in the bone marrow (BM); 2) the increase in rearranged DNA detected in BM was associated with disease progression and relapse; 3) a PCR-negative autograft seemed to lead to lasting molecular remission even when it was performed in patients with a low level of BM infiltration before transplant; and 4) allo-SCT made and maintained the BM PCR negative even in the presence of a greater tumor burden before SCT. Six of the nine patients having CR after SCT (four auto and two allo) are in continuous molecular remission.
Conclusions
In FL patients qualitative and quantitative PCR may provide data that can be helpful for the prognostic evaluation of tumor progression and the early detection of impending relapse by highlighting biological features such as the quality of the infused material, the tumor burden at transplant, and the behavior of tumor cells after transplant.
GribbenJ.G., FreedmanA.S., WooS.D., BlakeK., ShuR.S., FreemanG., LongtineJ.A., PinkusG.S., NadlerL.M.: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment.Blood,78: 3275–3280, 1991.
3.
GribbenJ.G., NeubergD., FreedmanA.S., GimmiC.D., PesekK.W., BarberM., SaporitoL., WooS.D., CoralF., SpectorN., RabinoweS.N., GrossbardM.L., RitzJ., NadlerL.M.: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma.Blood,81: 3449–3457, 1993.
4.
FreedmanA.S., GribbenJ.G., NeubergD., MauchP., SoifferR.J., AndersonK.C., PanditeL., RobertsonM.J., KroonM., RitzJ., NadlerL.M.: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission.Blood,88: 2780–2786, 1996.
5.
CorradiniP., AstolfiM., CherascoC., LadettoM., VoenaC., CaraccioloD., PileriA., TarellaC.: Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting.Blood,89: 724–731, 1997.
6.
Lopez-GuillermoA., CabanillasF., McLaughlinP., SmithT., HagemeisterF., RodriguezM.A., RomagueraJ.E., YounesA., SarrisA.H., PretiH.A., PughW., LeeM.S.: The clinical significance of molecular response in indolent follicular lymphomas.Blood,91: 2955–2960, 1998.
7.
FreedmanA.S., NeubergD., MauchP., SoifferR.J., AndersonK.C., FisherD.C., SchlossmanR., AlyeaE.P., TakvorianT., JallowH., KuhlmanC., RitzJ., NadlerL.M., GribbenJ.G.: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.Blood,94: 3325–3333, 1999.
8.
Lopez-GuillermoA., CabanillasF., McLaughlinP., SmithT., HagemeisterF., RodriguezM.A., RomagueraJ.E., YounesA., SarrisA.H., PretiH.A., PughW., LeeM.S.: Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series.Ann Oncol,11(suppl. 1): S137–S140, 2000.
9.
ApostolidisJ., GuptaR.K., GrenzeliasD., JohnsonP.W., PappaV.I., SummersK.E., SalamA., AdamsK., NortonA.J., AmessJ.A., MatthewsJ., BradburnM., ListerT.A., RohatinerA.Z.: High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up.J Clin Oncol,18: 527–536, 2000.
10.
LazzarinoM., ArcainiL., BernasconiP., AlessandrinoE.P., GargantiniL., CairoliR., OrlandiE., AstoriC., BrusamolinoE., PagnuccoG., ColomboA.A., CalatroniS., IaconaI., RegazziM.B., MorraE.: A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.Br J Haematol,116: 229–235, 2002.
11.
RambaldiA., LazzariM., ManzoniC., CarlottiE., ArcainiL., BaccaraniM., BarbuiT., BernasconiC., DastoliG., FugaG., GambaE., GargantiniL., GatteiV., LauriaF., LazzarinoM., MandelliF., MorraE., PulsoniA., RibersaniM., Rossi-FerriniP.L., RupoloM., TuraS., ZagonelV., ZajaF., ZinzaniP., ReatoG., FoaR.: Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.Blood,99: 856–862, 2002.
12.
MeijerinkJ.P.P., SmetsersTFCM, RaemaekersJ.M.M., BogmanMJJT, De WitteT., MensinkEJBM: Quantitation of follicular non-Hodgkin's lymphoma cells carrying t(14;18) by competitive polymerase chain reaction.Br J Haematol,84: 250–256, 1993.
13.
HosierG.A., BashR.O., BaiX., JainV., ScheuermannR.H.: Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma.Am J Pathol,154: 1023–1035, 1999.
14.
HirtC., DolkenG.: Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation.Bone Marrow Transplant,25: 419–426, 2000.
15.
Mandigers CM, Meijerink JP, Mensink EJ, Tonnissen EL, Hebeda KM, Bogman MJ, Raemaekers JM, Interzol (South-East Netherlands Comprehensive Cancer Centers Cooperative Group):Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma.Blood,98: 940–944, 2001.
16.
ChangC.C., BredesonC., JuckettM., LoganB., Keever-TaylorC.A.: Tumor load in patients with follicular lymphoma post stem cell transplantation may correlate with clinical course.Bone Marrow Transplant,32: 287–291, 2003.
17.
GalimbertiS., GuerriniF., MorabitoF., PalumboG.A., Di RaimondoF., PapineschiF., CaraccioloF., FazziR., CervettiG., CuzzocreaA., PetriniM.: Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by rituximab.Bone Marrow Transplant,32: 57–63, 2003.
18.
WilliamsM.E., SwerdlowS.H., MeekerT.C.: Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster.Leukemia,7: 1437–1440, 1993.
19.
PonczM., SchwartzE., BallantineM., SurreyS.: Nucleotide sequence analysis of the db-globin gene region in humans.J Biol Chem,258: 11599–11609, 1983.
20.
TarnuzzerR.W., MacauleyS.P., FarmerieW.G., CaballeroS., GrassemifarM.R., AndersonJ.T., RobinsonC.P., GrantM.B., Humphreys-BeherM.G., FranzenL., PeckA.B., SchultzG.S.: Competitive RNA templates for detection and quantification of growth factors, cytokines, extracellular matrix components and matrix metalloproteinases by RT-PCR.Biotechniques,20: 670–674, 1996.
21.
CrossN.C.P.: Quantitative PCR techniques and application.Br J Haematol,89: 693–697, 1995.
22.
VelasquezW.S., CabanillasF., SalvadorP., McLaughlinP., TuckerS., JagannathS., HagemeisterF.B., RedmanJ.R., SwanF.: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethazone (DHAP).Blood,71: 117–122, 1988.
23.
LaurentH., FlorenceB., ChristineM., ThierryA., RémyG., PatriceM., ChristianC.: Phenotypic, molecular, and functional characterization of human peripheral blood CD34+/THY1+ cells.Blood,87: 949–955, 1996.
24.
YoungR.C., LongoD.L., GlatsteinE.: The treatment of indolent lymphomas: Watchful waiting v aggressive modality treatment.Semin Hematol,25(suppl. 2): 11–16, 1988.
25.
VerdonckL.F., DekkerA.W., LokhorstH.M., PetersenE.J., NieuwenhuisH.K.: Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma.Blood,90: 4201–4205, 1997.
SummersK.E., DaviesA.J., MatthewsJ., JennerM.J., CorneliusV., AmessJ.A., NortonA.J., RohatinerA.Z.S., FitzgibbonJ., ListerT.A., GoffL.K.: The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction.Br J Haematol,118: 563–566, 2002.
28.
MandigersC.M., MeijerinkJ.P.P., RaemaekersJ.M.M., SchattenbergAVMB, MensinkEJBM: Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18).Lancet,352: 1522–1523, 1998.
29.
HochhausA., ReiterA., SaubeleS., ReichertA., EmigM., KaedaJ., SchultheisB., BergerU., ShepherdP.C.A., AllanN.C., HehlmannR., GoldmanJ.M., CrossN.C.P.: Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission.Blood,95: 62–66, 2000.
30.
HirtC., SchülerF., DölkenG.: Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab.Sem Cancer Biol,13: 223–231, 2003.
